Drug intelligence / Profile preview

FAV-Africa

Development stage: Unknown
Lead developer: Sanofi Pasteur
Modality: Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

FAV-Africa is a polyvalent antivenom composed of highly purified and pasteurized F(ab')2 fragments used for the treatment of snake envenomations in sub-Saharan Africa. It is administered by slow intravenous injection and has demonstrated safety and efficacy in clinical trials, with minimal adverse effects reported. The drug works by neutralizing venom toxins from multiple snake species, thereby preventing or reversing the toxic effects of envenomation. This antivenom addresses a critical need for effective snakebite treatment in African regions where such incidents are common.

Targets

Snake venom toxins (SAIMR Polyvalent Antivenom species)

Beyond the preview

Go deeper on FAV-Africa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FAV-Africa.

Explore the full profile